Close Menu

NEW YORK (GenomeWeb) – Editas Medicine announced today that it has exclusively licensed intellectual property related to the use of the genome-editing technology CRISPR for human therapeutic applications.

According to Editas, the IP — owned by Broad Institute, Harvard University, the Massachusetts Institute of Technology, Wageningen University, the University of Iowa, and the University of Tokyo — relates to a new CRISPR technology known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.